Online citations, reference lists, and bibliographies.

Results Of Treatment Of 385 Patients With Peritoneal Surface Spread Of Appendiceal Malignancy

P. Sugarbaker, D. Chang
Published 1999 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction: In the past, peritoneal carcinomatosis, regardless of primary tumor type, has always been a lethal condition. Recently, special treatments using cytoreductive surgery with peritonectomy procedures combined with perioperative intraperitoneal chemotherapy have resulted in long-term survival. Appendiceal malignancy with a low incidence of liver and lymph node metastases may be especially appropriate for these aggressive local regional treatments.Methods: All patients treated with surgery before January 1999 are included. Patients left with gross residual disease after surgery were not given intraperitoneal chemotherapy, but were later treated with intravenous chemotherapy. The intraperitoneal chemotherapy was given in the perioperative period, starting with mitomycin C at 12.5 mg/m2 for males and 10 mg/m2 for females. For patients whose pathology showed adenomucinosis, intraperitoneal chemotherapy was limited to treatment in the operating theater with heated mitomycin C. Patients with mucinous adenocarcinoma or pseudomyxoma/adenocarcinoma hybrid had, in addition to mitomycin C, five consecutive days of intraperitoneal 5-fluorouracil at 650 mg/m2 instilled in 1–1.5 liters of 1.5% dextrose peritoneal dialysis solution. A complete cytoreduction was defined as tumor nodules <2.5 mm in diameter remaining after surgery. The histopathology categorized the patients as having adenomucinosis, adenomucinosis/carcinomatosis hybrid, or mucinous carcinomatosis. A previous surgical score was used to estimate the extent of previous surgical procedures.Results: The morbidity of treated patients was 27% and the mortality was 2.7%. In a multivariate analysis, prognostic factors for survival included the completeness of cytoreduction (P < .0001), the histopathological character of the appendix malignancy (P < .0001), and the extent of previous surgical interventions (P = .001). Patients with a complete cytoreduction and adenomucinosis by pathology had a 5-year survival of 86%; with hybrid pathology, survival at 5 years was 50%. Incomplete cytoreduction had a 5-year survival of 20% and 0% at 10 years.Conclusions: Cytoreductive surgery and perioperative intraperitoneal chemotherapy can be used to salvage selected patients with peritoneal surface spread of appendiceal primary tumors. Similar strategies for other patients with peritoneal surface malignancy such as peritoneal carcinomatosis from colon or gastric cancer, peritoneal sarcomatosis, or peritoneal mesothelioma should be pursued.
This paper references
10.1016/s1055-3207(03)00048-6
Peritonectomy procedures.
P. Sugarbaker (1996)
Current methodologies for clinical assessment of patients with peritoneal carcinomatosis
P Jacquet (1996)
Morbidity and mortality of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique.Ann Surg Oncol 1999;6:790–6
AD Stephens (1999)
Pseudomyxoma peritonei: New concepts in diagnosis, origin, nomenclature, relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anatomic pathology.Chicago
BM Ronnett (1997)
10.1007/978-0-387-48993-3_15
Peritonectomy procedures.
Paul H Sugarbaker (1995)
10.1097/00000658-199402000-00001
Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon.
Paul H Sugarbaker (1994)
Intraperitoneal chemotherapy and cytoreductive surgery: Manual for physicians and nurses
PH Sugarbaker (1998)
10.1007/BF02625947
Peritoneal carcinomatosis from appendiceal cancer: A paradigm for treatment of abdomino-pelvic dissemination of gastrointestinal malignancy
Paul H Sugarbaker (2007)
Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary.
B M Ronnett (1997)
10.1007/s10434-999-0790-0
Morbidity and Mortality Analysis of 200 Treatments With Cytoreductive Surgery and Hyperthermic Intraoperative Intraperitoneal Chemotherapy Using the Coliseum Technique
A. D. Stephens (1999)
10.1007/978-1-4613-1247-5_24
Laser-mode electrosurgery.
P. Sugarbaker (1996)
10.1007/978-1-4613-1247-5_6
Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology.
P. Sugarbaker (1996)



This paper is referenced by
10.1038/sj.bjc.6604522
A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei
A. Farquharson (2008)
10.1016/j.currproblcancer.2009.06.003
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: overview and rationale.
Perry Shen (2009)
10.1002/9781119468868.CH16
Surgical Oncology Overview
M. Andrew Sicard (2017)
10.1007/s10434-004-1167-z
Long-Term Survival of Peritoneal Carcinomatosis of Colorectal Origin
Vic J. Verwaal (2004)
10.1016/j.ejso.2013.12.021
Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
Panagiotis Taflampas (2014)
Pseudomyxoma Peritonei Associated with Ovarian Tumor
Thanasak Sueblinvong (2017)
10.1177/145749691009900406
Clinical Presentation of Pseudomyxoma Peritonei
Petrus Järvinen (2010)
10.1080/07853890310020851
Carcinomatosis from gastrointestinal cancer
Paul H Sugarbaker (2004)
10.1016/j.amjsurg.2008.06.037
Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy.
Nathaniel P. Reuter (2008)
Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.
L. Sidéris (2009)
10.1634/theoncologist.2010-0052
Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy.
Thomas Winder (2010)
Consideraciones anestésicas en HIPEC
Norma Cuéllar-Garduño (2013)
10.1245/s10434-012-2845-x
The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Marcello Deraco (2012)
10.7863/ultra.32.9.1565
Role of preoperative sonography in the diagnosis and pathologic staging of pseudomyxoma peritonei.
Y. Li (2013)
10.1177/1457496913490463
Feasibility of Radical Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy For Pseudomyxoma Peritonei of Appendiceal Origin
P. Järvinen (2013)
"METÁSTASIS PERITONEAL DE CÁNCER GASTROINTESTINAL: BREVE HISTORIA"
Paul H Sugarbaker (2014)
10.15557/CGO.2014.0013
Ograniczenia w leczeniu chirurgicznym raka jajnika
Michał Makarewicz (2014)
10.1016/S0002-9610(02)00843-7
Morbidity and mortality associated with intraperitoneal chemotherapy for Pseudomyxoma peritonei.
Sonia A. Butterworth (2002)
10.1186/s12957-015-0682-7
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly
Y. Huang (2015)
10.1007/s00268-013-1988-7
Preoperative Carcinoembryonic Antigen Level Predicts Prognosis in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Emel Canbay (2013)
10.1097/DCR.0000000000001003
Prior Surgical Score: An Analysis of the Prognostic Significance of an Initial Nondefinitive Surgical Intervention in Patients With Peritoneal Carcinomatosis of a Colorectal Origin Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy
B K Paul (2018)
10.1016/J.EJSO.2019.07.008
Referral pathways and outcome of patients with colorectal peritoneal metastasis (CRPM).
Andreas Larentzakis (2019)
10.1016/j.currproblcancer.2009.06.002
The current role of hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of appendiceal tumors.
John H. IV Stewart (2009)
Chimiohyperthermie intrapéritonéale à l’oxaliplatinedans le traitement de la carcinose péritonéaled’origine appendiculaire
Éric Marcotte (2010)
Pseudomixoma peritoneal avanzado por adenocarcinoma mucinoso de apéndice
José Luis González González (2014)
10.1016/j.ejso.2015.02.016
Extensive surgical history prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with poor survival outcomes in patients with peritoneal mucinous carcinomatosis of appendiceal origin.
Vladimir Milovanov (2015)
10.1007/978-88-470-5711-1_7
Prevention and Management of Peritoneal Metastases from Gastrointestinal Cancer: A Short History of a Paradigm for Peritoneal Surface Malignancies
Paul H Sugarbaker (2015)
10.1007/978-3-319-28570-2_1
Peritoneal Dissemination of Gastrointestinal Tumors
Afshin Amini (2016)
10.1046/j.1365-2168.2001.01701.x
Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.
A. Witkamp (2001)
10.1016/j.gassur.2006.01.011
Staged laparoscopic infusion of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery
Amy Knutsen (2006)
10.1002/bjs5.93
Biological mesh is a safe and effective method of abdominal wall reconstruction in cytoreductive surgery for peritoneal malignancy
A Tzivanakis (2018)
10.1007/s00261-018-01888-y
Mucinous appendiceal neoplasms: classification, imaging, and HIPEC
David J Bartlett (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar